GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Evelo Biosciences Inc (OTCPK:EVLO) » Definitions » Forward Rate of Return (Yacktman) %

EVLO (Evelo Biosciences) Forward Rate of Return (Yacktman) % : 0.00% (As of Sep. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Evelo Biosciences Forward Rate of Return (Yacktman) %?

Yacktman defines forward rate of return as the normalized free cash flow yield plus real growth plus inflation. Evelo Biosciences's forward rate of return for was 0.00%.

The historical rank and industry rank for Evelo Biosciences's Forward Rate of Return (Yacktman) % or its related term are showing as below:

EVLO's Forward Rate of Return (Yacktman) % is not ranked *
in the Biotechnology industry.
Industry Median: 4.06
* Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.

Unlike the Earnings Yield %, the Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.


Evelo Biosciences Forward Rate of Return (Yacktman) % Historical Data

The historical data trend for Evelo Biosciences's Forward Rate of Return (Yacktman) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Evelo Biosciences Forward Rate of Return (Yacktman) % Chart

Evelo Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Forward Rate of Return (Yacktman) %
Get a 7-Day Free Trial - - - - -

Evelo Biosciences Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Forward Rate of Return (Yacktman) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Evelo Biosciences's Forward Rate of Return (Yacktman) %

For the Biotechnology subindustry, Evelo Biosciences's Forward Rate of Return (Yacktman) %, along with its competitors' market caps and Forward Rate of Return (Yacktman) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Evelo Biosciences's Forward Rate of Return (Yacktman) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Evelo Biosciences's Forward Rate of Return (Yacktman) % distribution charts can be found below:

* The bar in red indicates where Evelo Biosciences's Forward Rate of Return (Yacktman) % falls into.


;
;

Evelo Biosciences Forward Rate of Return (Yacktman) % Calculation

Forward Rate of Return is a concept that Don Yacktman uses in his investment approach. Yacktman explained the forward rate of return concept in detail in his interview with GuruFocus. Yacktman defines forward rate of return as the normalized free cash flow yield plus real growth plus inflation. He said in the interview (March 2012, when the S&P 500 was at about 1400):

If the business is stable, this calculation is fairly straightforward. For instance, on the S&P 500 we would normalize earnings. We would then calculate what percentage of those earnings are not reinvested in the underlying businesses and are therefore free. Historically, for the S&P 500, this has been just under 50% of earnings. Currently, we expect the S&P to earn about 70 on a normalized basis, a number which is far below reported earnings due to our adjusting for record high profit margins. $70 X ½ / 1400 gives you a normalized free cash flow yield of approximately 2.5%.

The historical real growth rate of the S&P 500 (companies) is about 1.5%. Assuming an inflation rate of 2.5%, the forward rate of return on an investment in the S&P 500 is about 6.5% today (2.5% free cash flow yield plus 1.5% real growth plus 2.5% inflation).

Evelo Biosciences's Forward Rate of Return of Sep. 2023 is

Forward Rate of Return=Normalized Free Cash Flow/Price+5-Year EBITDA Growth Rate
=0/3.92+0
=0.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Evelo Biosciences  (OTCPK:EVLO) Forward Rate of Return (Yacktman) % Explanation

Unlike the Earnings Yield, the Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.

For the growth part of the Forward Rate of Return calculation, GuruFocus uses the 5-year average growth rate of EBITDA per share as the growth rate, and the growth rate is always capped at 20%. For the Free Cash Flow we use per share data averaged over five years. The reason we use five years is to make it comparable to the growth rate.


Be Aware

In the Forward Rate of Return calculation, the growth rate is added directly to today's free cash flow yield. Therefore the calculation is reliable only if the company can grow at the same rate in the future as it did in the past. Investors should pay close attention to this when researching growth stocks. A more accurate measurement for return is Return on Capital.


Evelo Biosciences Forward Rate of Return (Yacktman) % Related Terms

Thank you for viewing the detailed overview of Evelo Biosciences's Forward Rate of Return (Yacktman) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Evelo Biosciences Business Description

Industry
Traded in Other Exchanges
N/A
Address
620 Memorial Drive, 5th Floor, Cambridge, MA, USA, 02139
Evelo Biosciences Inc is a United States-based biotechnology company. It is engaged in discovering and developing a new class of orally delivered investigational medicines that are intended to act on cells in the small intestine to produce therapeutic effects throughout the body. Its lead product candidate under development is EDP1815, which is for the treatment of inflammatory diseases and the hyperinflammatory response associated with COVID-19. Other products in the pipeline include EDP1867 and EDP2939 for the treatment of inflammatory disease and EDP1908 for the treatment of cancer.
Executives
Simba Gill director, officer: President & CEO 515 GALVESTON DR, REDWOOD CITY CA 94063
Mark Bodmer officer: See Remarks C/O EVELO BIOSCIENCES, INC., 620 MEMORIAL DRIVE, SUITE 200, CAMBRIDGE MA 02139
Marella Thorell officer: Chief Financial Officer 1226 CHARTER LANE, AMBLER PA 19002
Duncan Mchale officer: Chief Medical Officer C/O EVELO BIOSCIENCES, INC., 620 MEMORIAL DRIVE, SUITE 200, CAMBRIDGE MA 02139
Alexander C Reynolds director C/O EVELO BIOSCIENCES, INC., 620 MEMORIAL DRIVE, SUITE 200, CAMBRIDGE MA 02139
Horizon Technology Finance Corp 10 percent owner 312 FARMINGTON AVENUE, FARMINGTON CT 06032
Jeffrey R. Moore director C/O EVELO BIOSCIENCES, INC., 620 MEMORIAL DRIVE, SUITE 200, CAMBRIDGE MA 02139
Flagship Ventures Fund Iv, L.p. 10 percent owner 55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Robert L. Rosiello director 400 SOMERSET CORPORATE BOULEVARD, BRIDGEWATER NJ 08807
Stephen J Carriere officer: Principal Accounting Officer
David R Epstein director INTERNATIONAL FLAVORS & FRAGRANCES INC., 521 W. 57TH STREET, NEW YORK NY 10019
Lord Ara Darzi director C/O EVELO BIOSCIENCES, INC., 620 MEMORIAL DRIVE, SUITE 200, CAMBRIDGE MA 02139
Flagship Pioneering Fund Vii, L.p. 10 percent owner 55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Flagship Pioneering Fund Vii General Partner Llc 10 percent owner 55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Tonya Williams director C/O EVELO BIOSCIENCES, INC., 620 MEMORIAL DRIVE, SUITE 200, CAMBRIDGE MA 02139